Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Targovax ASA ( (GB:0RIS) ) has shared an announcement.
Circio Holding ASA has announced a share capital increase following the conversion of convertible bonds by Atlas Special Opportunities, LLC, bringing the new share capital to NOK 61,345,650. This development signifies a strategic financial move that could bolster Circio’s position in the biotechnology sector, particularly as it continues to innovate in nucleic acid and viral therapeutics through its circVec platform and immuno-oncology program.
More about Targovax ASA
Circio Holding ASA is a biotechnology company specializing in the development of circular RNA vector expression technology aimed at advancing gene and cell therapies. The company has created a unique platform, circVec, which enhances protein expression significantly compared to traditional mRNA systems. Circio is also working on its immuno-oncology program, TG01, targeting RAS-mutated cancers through collaborations and clinical trials in Norway and the USA.
Average Trading Volume: 1,387,486
Current Market Cap: NOK63.8M
See more insights into 0RIS stock on TipRanks’ Stock Analysis page.